Nucleo CMF forte lyophilisate for injection solution 61 mg with solvent 2 ml No. 3

Use of the drug Nucleo cmf forte

Nucleo CMF Forte capsules are taken orally. Adults are prescribed 1–2 capsules 2 times a day; children over 5 years old - 1 capsule 2 times a day. Nucleo CMF Forte capsules can be taken before or after meals. The recommended duration of treatment is at least 10 days. If necessary, taking capsules can be extended for 20 days. Nucleo CMF Forte injection for intramuscular administration. Before administration, the solvent must be added to the ampoule with lyophilized powder. For adults, including elderly patients, and adolescents over the age of 14 years, 1 injection of the drug Nucleo CMF Forte is administered once a day. Children aged 2–14 years are recommended to administer 1 injection of Nucleo CMF Forte every 2 days. Recommended course of treatment: 1 injection per day for 3 or 6 days, then continue treatment using the drug in oral form - 1-2 capsules 2 times a day for 10 days. If there are medical indications, the drug may be extended for 20 days.

Pharmacological action of Nucleo c.m.f. forte contains pyrimidine nucleotides - cytidine-5-monophosphate (CMP) and uridine-5-triphosphate (UTP), which are necessary components in the treatment of diseases of the nervous system. Phosphate groups are necessary in the body for the reaction of monosaccharides with ceramides, which results in the formation of cerebrosides and phosphatidic acids, which mainly make up sphingomyelin, the main component of the myelin sheath of nerve cells, as well as for the formation of glycerophospholipids. Sphingolipid and glycerophospholipids provide demyelination of nerve fibers, regeneration of axons and myelin sheath in case of damage to the peripheral nervous system and help restore the correct conduction of nerve impulses, and also restore trophism of muscle tissue. As a result, mobility and sensitivity improve, inflammation, pain and numbness decrease. Also, cytidine 5-monophosphate and uridine 5-triphosphate are precursors of DNA and RNA - nucleic acids necessary for the processes of cellular metabolism and protein synthesis. UTP is also an energy source during muscle fiber contraction

Indications for use

Neuralgia, neuritis nervus trigeminus (nervus facialis), plexitis, osteoarticular neuralgia (lumbago, lumbodynia, lumboischialgia, radiculopathy), intercostal neuralgia and herpes zoster, metabolic neuralgia (consequences of alcohol addiction, complications of diabetes (polyneuropathy)), ganglionitis, verte fermentative pain syndrome, Bell's palsy, myopathy, carpal tunnel syndrome.

Mode of application

Nucleo c.m.f. forte capsules The drug can be used by adults and children. Adults: 1 to 2 capsules twice daily; Children are prescribed 1 capsule twice a day from the age of 5, can be taken before or after meals. The course of treatment is at least 10 days. If indicated, the drug can be extended up to 20 days. Nucleo c.m.f. forte ampoules for intramuscular administration Before administration, it is necessary to dissolve the powder with the supplied solvent. Adults, as well as elderly people and children under 14 years of age are prescribed 1 injection once every 24 hours. Children from 2 to 14 years old are prescribed 1 injection every 48 hours. The course of treatment lasts from three to six days, then continue oral administration of the drug from 1 to 2 capsules twice a day for 10 days. If indicated, the drug can be extended up to 20 days.

Side effects

Not described.

Contraindications

An allergic reaction to the components of the drug may occur. Age under two years is a contraindication to the use of Nucleo c.m.f. forte.

Pregnancy

Taking the drug is not contraindicated, but it is necessary to evaluate the ratio of the real benefits of taking the drug and the potential risk to the intrauterine fetus, since there is no information regarding the safety of use during pregnancy.

Overdose

The drug is low-toxic, the likelihood of overdose is very low even if the therapeutic dose is exceeded.

Release form

Capsules, blister 30 pcs. To prepare a solution for injection - lyophilized powder (61 mg of active substance) in 2 ml ampoules; No. 3 per pack.

Storage conditions

Store at room temperature (no more than 30 degrees Celsius).

Compound

1 capsule contains cytidine-5-monophosphate disodium 5 mg, uridine-5-trisodium phosphate, uridine-5-diphosphate disodium, uridine-5-monophosphate disodium only 63 mg (corresponding to 1.33 0 mg of pure uridine). Excipients: citric acid, Na citrate dihydrate, Mg stearate, Aerosil 200, mannitol. 1 ampoule with lyophilized powder contains cytidine-5-monophosphate disodium 10 mg, uridine-5-trisodium phosphate, uridine-5-diphosphate disodium, uridine-5-monophosphate disodium only 6 mg (corresponding to 2.660 mg of pure uridine). Excipients: mannitol; solvent: water, Na chloride. Attention! The description of the drug on this page is simplified. Before purchasing and using the drug, consult your doctor or pharmacist, and also read the instructions approved by the manufacturer. Information about the drug is provided for informational purposes only and should not be used as a guide to self-medication. ATTENTION! This section is provided for informational purposes only and is not a catalog or price list of our company. To obtain information about the availability of drugs, call + 99871 202 0999 Pharmacy Network Helpline 999.

Reviews and recommendations from doctors

The drug Nucleo CMF Forte, reviews of which position it as an effective remedy in the treatment of PNS pathologies, is a unique drug that has no contraindications, side effects and does not interact with other drugs used in complex therapy.

Nucleo CMF Forte capsules, reviews of which can be found in various sources, have the following effects:

• Active regeneration of nerve fiber sheaths;
• Restoring the conductivity of nerve fibers, normalizing the correct conduction of impulses;
• Restoration of muscle trophism (cell nutrition processes that contribute to the preservation of the structure and function of organs and tissues);
• Improving mobility and sensitivity of the damaged area;
• Reducing pain, symptoms of inflammatory processes in affected tissues, and numbness.

The effectiveness of the drug has been proven by practical observations and retrospective studies. The majority of patients receiving Nucleo CMF Forte therapy noted an improvement in the dynamics of recovery, a rapid return to a normal lifestyle, and a significant improvement in the quality of life.

Pharmacodynamics of the drug

Pathology of the peripheral nervous system (PNS) is one of the most common reasons for visiting a neurologist. PNS dysfunctions occupy a leading place among the causes of long-term disability in patients.

The peripheral nervous system is an internal mechanism of the body that connects the central nervous system (brain and spinal cord) with other organs. The PNS has not received natural powerful defense mechanisms, unlike the central nervous system, which is protected by the bone skeleton and the blood-brain barrier, which makes the PNS very vulnerable to external mechanical damage, as well as to the effects of negative factors.

There are two types of neurons involved in the peripheral nervous system:

• Sensitive sensory neurons that transmit impulses to the central nervous system;
• Sensitive motor neurons that transmit impulses from the central nervous system.

To date, more than 100 factors have been identified that have a negative impact on neurons and contribute to disruption of their function (impulse conduction), among which are:

• Toxins;
• Diseases of various nature;
• Viral and bacterial infections of the body;
• Medications;
• Unfavorable environmental conditions;
• Mechanical injuries.

There are four types of reactions of nerve fibers to damaging factors, most of which Nucleo CMF Forte is able to stop, restoring the sensitivity of the nerve process:

• Reaction of Wallerian degeneration (to the intersection of the nerve process);
• Axonopathy, consisting of degeneration or atrophy of the nerve fiber (the least studied pathology of the PNS);
• Partial demyelination (segmental myelinopathy - damage to the myelin sheaths with preservation of the nerve itself);
• Neuronopathy is a primary disorder of the neuron body.

In modern medical practice, treatment of PNS pathologies mainly comes down to relieving the symptomatic complex without eliminating the causes, which makes treatment ineffective and lengthy.

Nucleo CMF Forte is a unique drug due to its composition. Pyrimidine nucleotides, used as the basis for the innovative pyrimidine complex, play a leading role in the restoration of many morphological structures (elements) of the peripheral nervous system and normalize the transmission of impulses to and from the central nervous system.

Pyrimidine nucleotides in the innovative drug:

• Cytidine 5-monophosphate (CMP) is a nucleotide involved in the synthesis of complex lipid complexes that form the neuronal membrane. This nucleotide is the main structural component of the myelin sheath (the electrically insulating sheath that covers axons). Damage to the myelin sheath in some diseases leads to impaired coordination and balance. CMP is the precursor of the basic nucleic acids RNA and DNA, which play a major role in cellular metabolism;
• Uridine-5-triphosphate (UTP), a nucleotide in the composition of the drug, complements the action of CMP, and also, acting as a coenzyme, stimulates the synthesis of glycolipids of myelin sheaths.

Thus, the drug Nucleo CMF Forte promotes the rapid regeneration of nerve fibers and their myelin sheaths after damage to the PNS nerves.

Nucleo CMF forte lyophilisate for injection solution 61 mg with solvent 2 ml No. 3

Indications

The use of a new drug based on pyrimidine nucleotides has brought traditional therapy for PNS pathologies to a qualitatively new level. Nucleo CMF Forte is an effective remedy for the following diseases of the PNS:

• Neuropathies of various etiologies - disorders of the functioning of the nervous system of the osteoarticular, metabolic (including alcoholic, diabetic polyneuropathies), infectious nature;
• Neuralgia, neuritis, plexitis;
• Vertebrogenic pain syndrome;
• Shingles (Herpes Zoster);
• Myopathies;
• Carpal tunnel syndrome;
• Bell's palsy.

The drug Nucleo CMF Forte, the instructions of which provide for its use only as prescribed by the attending physician, is available in two forms: capsules and ampoules. The drug is indicated for both children and adults. When using Nucleo CMF Forte, the instructions do not indicate contraindications, side effects or interaction reactions with other drugs. Nucleo CMF Forte is approved for pregnant and breastfeeding patients. However, in such a situation, the drug should be used only in consultation with a doctor.

The drug does not in any way affect a person’s ability to drive vehicles and other mechanisms requiring increased attention. When treating with the new generation drug Nucleo CMF Forte, the instructions regulate the dosage and duration of taking the drug.

Nucleo C.M.F. forte No. 30 caps.

Instructions for medical use of the drug Nucleo C.M.F. FORTE Trade name Nucleo C.M.F. FORTE International nonproprietary name No Dosage form Capsules Composition One capsule contains active substances: cytidine 5′-disodium monophosphate 5.00, uridine 5′-trisodium triphosphate, uridine 5′-disodium diphosphate, uridine 5′-disodium monophosphate (total) 3.00 (equivalent to content uridine) (1.33). excipients: citric acid, sodium citrate dihydrate, magnesium stearate, colloidal silicon dioxide, mannitol. capsule composition: black iron oxide E172, titanium dioxide E171, gelatin, indigo carmine E132. Description Hard gelatin capsules No. 2, gray body, blue cap. The contents of the capsules are white powder, hygroscopic. Pharmacotherapeutic group Other drugs for the treatment of diseases of the nervous system ATC code N07XX Pharmacological properties Pharmacokinetics The components of this drug are of organic origin, which are already present in biological fluids, making it difficult to conduct pharmacokinetic studies of the drug, and this served as the basis for conducting a study using a product labeled with radioactive isotopes. The objectives of this study were to evaluate the absorption and pharmacokinetics of UMP, CMP, and UTP. After administration of 14C-UMP at a dose of 4.97 mg/kg, maximum plasma concentrations (Cmax) of 1.749 mg/kg were achieved after 10 minutes. The radioactivity was then rapidly eliminated with half-lives of 0.5 and 0.6 hours for alpha distribution and beta elimination, respectively. After application of 14C-CMF at a dose of 4.83 mg/kg, a Cmax value of 1.567 mg/kg was achieved after 20 minutes. The radioactivity was then rapidly cleared with corresponding half-lives of 1.0 and 3.8 hours. After application of 14C-UTP at a dose of 4.86 mg/kg, a Cmax value of 1.291 mg/kg was achieved after 20 minutes. The radioactivity was then rapidly cleared with corresponding half-lives of 1.2 and 5.0 hours. The same metabolic pathway was found in UMP and UTP, i.e. rapid transformation through uracil to at least one more polar radioactive fraction. The CMP compound was rapidly converted to cytosine, uracil, and at least one more polar radioactive fraction. Therefore, cytosine was mainly converted to uracil. These results indicate that uracil was metabolized less rapidly in the blood in the presence of cytosine, which was formed from the parent compound ingested, CMP. Pharmacodynamics Nucleo CMP Forte contains a number of nucleotides: cytidine monophosphate (CMP), uridine triphosphate (UTP), which are widely used to treat diseases of the PNS (peripheral nervous system). From a biochemical point of view, the action of these two components can be described as follows: CMP takes part in the synthesis of a complex of lipids that form the neuronal membrane, mainly sphingomyelin, the main component of the myelin sheath. CMP is also a precursor to nucleic acids (DNA and RNA), which in turn are the main elements of cellular metabolism (for example, in protein synthesis). UTP acts as a coenzyme in the synthesis of glycolipids, neuronal structures and the myelin sheath, complementing the action of CMP. In addition, it acts as a source of energy during muscle contraction. In general, CMP and UTP are involved in the synthesis of phospholipids and glycolipids, which mainly constitute the myelin sheath and other nerve structures. This leads to intense metabolic activity, which in turn promotes the process of regeneration of the myelin sheath, regulating demyelination in peripheral nerve injuries. Thus, the combination of the actions of CMP and UTP promotes the regeneration of the myelin sheath, the correct conduction of nervous stimulation and the restoration of muscle trophism. Nucleo C.M.F. FORTE provides the body with phosphate groups necessary for combining monosaccharides with ceramines to form nerve sheaths, and phosphatidic acids that make up sphingomyelin and glycerophospholipids - the main components of the myelin sheath. Thus, a stable trophic effect, more complete maturation and regeneration of axonal nerve fibers are ensured. As a result, inflammation is reduced and the sensitivity of the damaged area of ​​the axon is normalized, which helps restore axonal transport. Indications for use - sciatica - radiculitis - diabetic polyneuropathy - alcoholic polyneuritis - herpes zoster - neuralgia of the facial, trigeminal, intercostal nerves - lumbago Method of use NUCLEO C.M.F. FORTE is prescribed orally: Adults: 1-2 capsules 3 times a day from 1 month to 3 months. The course of treatment, if necessary, is up to 6 months. Side effects Not reported, but if you experience any adverse reactions associated with the use of the drug, consult your doctor. Contraindications - hypersensitivity to the components of the drug - children and adolescents up to 18 years old Drug interactions Not known Special instructions Pregnancy and lactation. The advisability of taking it is determined depending on the predominance of the benefits of taking it over the potential risk. Peculiarities of the effect on the ability to drive vehicles or other potentially dangerous mechanisms. Does not affect Overdose Due to the low toxicity of the drug, the likelihood of an overdose is low. Release form and packaging 15 capsules are placed in a blister pack made of polyvinyl chloride film and aluminum foil. 2 contour packages together with instructions for medical use in the state and Russian languages ​​are placed in a cardboard pack. Storage conditions Store at a temperature not exceeding +300C. Keep out of the reach of children! Shelf life: 2 years Do not use after expiration date. Conditions for dispensing from pharmacies By doctor's prescription. Manufacturer Ferrer International, S.A., Gran Via Carlos III, 94, 08028 Barcelona, ​​Spain. Marketing authorization holder Ferrer International, S.A., Gran Via Carlos III, 94, 08028 Barcelona, ​​Spain. Address of the organization that accepts claims from consumers regarding product quality on the territory of the Republic of Kazakhstan Representative office in the Republic of Kazakhstan: “Medial D&P LTD” Address: 050050 Almaty, st. Tabachnozavodskaya, 20, phone +77272954882, fax – 2954881, e-mail: [email protected]